公开(公告)号：US20200253980A1

公开(公告)日：2020-08-13

申请号：US16820886

申请日：2020-03-17

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  XIZHONG Huang ,  Joseph Lehar ,  Hui-Qin Wang

IPC: A61K31/53 ,  A61K45/06 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20190350935A1

公开(公告)日：2019-11-21

申请号：US16526027

申请日：2019-07-30

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  XIZHONG Huang ,  Joseph Lehar ,  Hui-Qin Wang

IPC: A61K31/53 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4745 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/427 ,  A61K31/4709

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.